	US 12,404,337 B2
	Compositions, doses, and methods for treatment of thyroid eye disease
Denis O'Shaughnessy, Waltham, MA (US); and Barrett Katz, Waltham, MA (US)
Assigned to Viridian Therapeutics, Inc., Waltham, MA (US)
Filed by Viridian Therapeutics, Inc., Waltham, MA (US)
Filed on Dec. 20, 2023, as Appl. No. 18/391,233.
Application 18/391,233 is a continuation of application No. 17/818,798, filed on Aug. 10, 2022, abandoned.
Claims priority of provisional application 63/261,744, filed on Sep. 28, 2021.
Claims priority of provisional application 63/260,133, filed on Aug. 10, 2021.
Prior Publication US 2024/0343812 A1, Oct. 17, 2024
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 5/14 (2006.01); A61P 27/02 (2006.01); A61P 37/00 (2006.01)

CPC C07K 16/2863 (2013.01) [A61P 5/14 (2018.01); A61P 27/02 (2018.01); A61P 37/00 (2018.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01)]

8 Claims

1. A method of treating active thyroid eye disease (TED) in a subject in need thereof, the method comprising:

administering a first dose of a pharmaceutical composition comprising an anti-IGF-IR antibody at 10 mg/kg, and

administering a subsequent dose of the pharmaceutical composition comprising the anti-IGF-1R antibody at 10 mg/kg three weeks after the first dose, such that the subject has a reduction in proptosis or an improvement in CAS score within 6 weeks of the first dose,

wherein administration of the antibody is by intravenous infusion,

wherein the anti-IGF-1R antibody comprises a light chain and a heavy chain, and

wherein the heavy chain comprises a HCDR1 of SEQ ID NO: 7, a HCDR2 of SEQ ID NO: 8, and a HCDR3 of SEQ ID NO: 9 and the light chain comprises a LCDRI of SEQ ID NO: 4,a LCDR2 of SEQ ID NO: 5 and a LCDR3 of SEQ ID NO: 6.